Several Californians have initiated a class-action lawsuit against Sutter Health and MemorialCare, alleging that the healthcare providers utilized an AI transcription tool to record patient-doctor conversations without obtaining proper consent. The lawsuit, filed on April 8, 2026, in the U.S. District Court for the Northern District of California, contends that the use of Abridge AI during medical consultations violated both state and federal privacy laws.
The plaintiffs assert that within the past six months, they received medical care at various Sutter and MemorialCare facilities where Abridge AI was employed to capture and process their confidential communications with physicians. According to the complaint, patients were not adequately informed that their medical conversations would be recorded by an artificial intelligence platform, transmitted outside the clinical setting, or processed through third-party systems.
Abridge AI, developed by the Pittsburgh-based company Abridge, is designed to automate clinical documentation by recording and summarizing medical conversations in real-time. The platform integrates directly with electronic health records (EHR) systems, aiming to reduce the administrative burden on clinicians and enhance patient care. Abridge has been adopted by numerous health systems across the United States, including Sutter Health and MemorialCare, to streamline clinical documentation processes.
In response to the lawsuit, a spokesperson for Sutter Health stated, “We are committed to protecting patient privacy and ensuring compliance with all applicable laws and regulations. We are reviewing the allegations and will respond appropriately.” MemorialCare has yet to issue a public statement regarding the litigation.
This legal action underscores the growing tension between technological advancements in healthcare and patient privacy rights. As AI tools become increasingly integrated into medical practice, healthcare providers must navigate the complex landscape of consent and confidentiality to maintain trust and comply with legal standards.
The outcome of this case could have significant implications for the deployment of AI technologies in clinical settings, potentially influencing policies on patient consent and data handling practices nationwide.